The Endocannabinoid System: a new anti-inflammatory target in rheumatoid arthritis
Abstract Rheumatoid arthritis (RA) is characterised by the loss of regulatory T cell (Treg) mediated suppression of inflammatory T helper cells. RA patients with loss of immune tolerance display elevated levels of circulating pro-inflammatory cytokines. The endocannabinoid system (ES) present on imm...
Saved in:
Published in: | The Journal of immunology (1950) 2020-05, Vol.204 (1_Supplement), p.237-237.7 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | eng |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Abstract Rheumatoid arthritis (RA) is characterised by the loss of regulatory T cell (Treg) mediated suppression of inflammatory T helper cells. RA patients with loss of immune tolerance display elevated levels of circulating pro-inflammatory cytokines. The endocannabinoid system (ES) present on immune cells may represent a novel target for development of anti-inflammatory treatments. We screened the therapeutic potential of a phytocannabinoid compound, GL1b, in an ex vivo, peripheral blood mononuclear cell (PBMC) inflammatory model. PBMCs were cultured with CD3/CD28 and IL-2 to activate and expand T cells. Inflammation was induced by phorbol 12-myristate-13-acetate (PMA)/ionomycin activation, over 4 hours. Inflamed PBMCs were treated with 0, 10, 20 and 50 μM GL1b for 24 hours, then harvested for flow cytometry analysis of Tregs. Cytokine mRNA expression and conditioned media concentration were analysed with qRT-PCR and ELISA, respectively. Results will be fed into in silico model. 50 μM GL1b significantly suppressed the total Treg population (p |
---|---|
ISSN: | 0022-1767 1550-6606 |